WaveMan
WaveMan · Company
OLMA · Olema Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

OLMA Olema Pharmaceuticals (OLMA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001750284
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
98
13F, latest reported quarter

What the filings say about OLMA

Insiders, 180 days
-$291.2K net sold
1 seller · 0% of sales under a 10b5-1 plan

Olema Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Olema Pharmaceuticals, Inc. insiders sold a net $291.2K of stock across 139 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Harmon Cyrus
Director
SELL
2026-07-27 SECtraded 2026-07-24
12,500
$146.4K
-44.8%
Context
  • 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on Jul 23, 2026.
  • The trade is 1.8% of the 702,770 shares held after it.
  • No other insider sold within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harmon Cyrus sold about $146.4K of OLMA on Jul 24, 2026; 98 funds added in the latest 13F quarter.
Harmon Cyrus
Director
SELL
2026-07-27 SECtraded 2026-07-23
12,500
$144.7K
-44.8%
Context
  • 45 earlier Form 4 trades (code P or S) here by this insider (45 sales), the last on Jan 20, 2026.
  • The trade is 1.7% of the 715,270 shares held after it.
  • No other insider sold within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harmon Cyrus sold about $144.7K of OLMA on Jul 23, 2026; 98 funds added in the latest 13F quarter.
Mitchell Shawnte
CHIEF LEGAL OFFICER
SELL
2026-03-05 SECtraded 2026-03-04
233
$5.8K
-70.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 3, 2026.
  • No other insider sold within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF LEGAL OFFICER Mitchell Shawnte sold about $5.8K of OLMA on Mar 4, 2026; 98 funds added in the latest 13F quarter.
Mitchell Shawnte
CHIEF LEGAL OFFICER
SELL
2026-03-05 SECtraded 2026-03-04
24,767
$600.6K
-70.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 3, 2026.
  • The trade is 10629.6% of the 233 shares held after it.
  • No other insider sold within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF LEGAL OFFICER Mitchell Shawnte sold about $600.6K of OLMA on Mar 4, 2026; 98 funds added in the latest 13F quarter.
Mitchell Shawnte
CHIEF LEGAL OFFICER
SELL
2026-03-05 SECtraded 2026-03-03
15,000
$345.1K
-70.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF LEGAL OFFICER Mitchell Shawnte sold about $345.1K of OLMA on Mar 3, 2026; 98 funds added in the latest 13F quarter.
139 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 134 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$291.2K over 180 days
below 51% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
98 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
24.8% of the float short (float per yahoo 2026-10-26) · 10.2 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch OLMA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.7%12M
-22%+98%+218%+337%2025-102025-122026-022026-042026-062026-082026-10 2025-12-19 · CLARK IAN T sold $5.7M2026-01-15 · Kovacs Shane William Charles sold $2.9M2025-12-22 · Zojwalla Naseem sold $2.8M2025-12-23 · Zojwalla Naseem sold $2.8M2025-12-19 · Zojwalla Naseem sold $1.6M2026-01-13 · Myles David C. sold $1.4M2025-12-19 · Myles David C. sold $1.3M2025-12-19 · CLARK IAN T sold $1.3M2026-01-14 · Myles David C. sold $1.0M2025-12-19 · CLARK IAN T sold $862.1K2026-03-04 · Mitchell Shawnte sold $600.6K2026-01-14 · Myles David C. sold $428.9K2025-12-19 · Zojwalla Naseem sold $373.8K2026-03-03 · Mitchell Shawnte sold $345.1K2026-01-12 · Myles David C. sold $283.4K2026-01-20 · Harmon Cyrus sold $268.8K2025-12-19 · Myles David C. sold $189.8K2026-07-24 · Harmon Cyrus sold $146.4K2026-07-23 · Harmon Cyrus sold $144.7K2026-01-13 · Kovacs Shane William Charles sold $107.1K2026-01-14 · Harmon Cyrus sold $101.6K2025-12-22 · Harmon Cyrus sold $82.2K2025-12-19 · Myles David C. sold $34.4K2026-03-04 · Mitchell Shawnte sold $5.8K2026-01-13 · Myles David C. sold $5.7K2026-07-24 · Harmon Cyrus filed to sell $146.4K2026-07-23 · Harmon Cyrus filed to sell $144.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OLMA: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
12,143,062 sh
$151.9M
Paradigm Biocapital Advisors LP
8,670,576 sh
$108.5M
Jupiter Topco LLC
7,094,413 sh
$88.8M
Bain Capital Life Sciences Investors, LLC
7,085,249 sh
$88.6M
BlackRock, Inc.
6,714,691 sh
$84.0M

Congress trades in OLMA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OLMA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Harmon Cyrus
Filed 2026-07-24
$146.4K
Harmon Cyrus
Filed 2026-07-23
$144.7K

OLMA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$360.6K position · as of 2026-07-31
0.8%
Dunham Small Cap Growth Fund
$566.4K position · as of 2026-07-31
0.7%
ALPS Medical Breakthroughs ETF
$1.1M position · as of 2026-05-31
0.7%
PGIM Jennison Health Sciences Fund
$8.7M position · as of 2026-05-29
0.6%
Tema Oncology ETF
$1.1M position · as of 2026-05-31
0.6%
Franklin Biotechnology Discovery Fund
$6.5M position · as of 2026-07-31
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
3 active
2
Phase 3
2 active
1
Multi-phase
0 active
What changed recently
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Ever
2026-09-16 · Recruiting → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.2M
$25.2M
$2.0M
+920%
n/a
2024
$8.1M
-$4.6M
$3.6M
+138%
n/a
2023
$3.2M
$22.3M
$1.4M
+473%
n/a
2022
$6.0M
-$3.3M
$2.3M
-95%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $291.2K sold by insiders over 180 days, 98 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OLMA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-52.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-47.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-56.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$178.7M-$142.3M-$105.0M-$107.0M
Net income-$162.5M-$129.5M-$96.7M-$104.8M
EPS (diluted)-1.87-2.20-2.14-2.62
Operating cash flow-$146.7M-$104.4M-$83.7M-$82.1M
Cash$48.3M$139.5M$68.5M$23.7M
SEC XBRL, fiscal years, as known on 2026-10-27

OLMA Stock Sonar score 4/7 axes

Find similar shapesCompare

OLMA ranks highest on institutional and government (67th percentile) and profitability (47th), and lowest on risk and compliance (8th), among Pharma & Biotech peers.

Profitability
47
Inputs
  • Return on equity-52.7% · 52 pct, sector of 545
  • Return on assets-47.1% · 46 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-56.5% · 44 pct, sector of 576
Insider conviction
23
Inputs
  • Net Form 4 buying (codes P and S), 180d-$291K · 47 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
67
Inputs
  • Funds adding, latest quarter98 · 67 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
8
Inputs
  • Short interest, % of float+24.8% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OLMA filings, in plain words

Are Olema Pharmaceuticals insiders buying or selling OLMA?

In the 180 days to 2026-10-27, Olema Pharmaceuticals insiders were net sellers, a net $291.2K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-27, Olema Pharmaceuticals insiders were net sellers of OLMA, a net $291.2K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies